Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that ...

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the ...

KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Jones Trading ...

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have earned an average recommendation of “Buy” from ...

KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat for hereditary angioedema ...

TD Cowen analyst Stacy Ku maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price target of $30.00.

In a report released today, Paul Matteis from Stifel Nicolaus reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report), ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID ...

KalVista Pharmaceuticals (NASDAQ:KALV), Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label... ByInvesting.com • Mar 25, 2025 H.C. Wainwright maintains Buy on ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase ...